Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told

Law360, Philadelphia (June 24, 2014, 4:29 PM EDT) -- Plaintiffs pursuing class actions against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over allegedly improper pay-for-delay settlements aimed at barring generic versions of the cholesterol drug Niaspan from entering the market have failed to show they were injured by the deal, a Pennsylvania federal judge heard Tuesday.

Stuart Senator of Munger Tolles & Olson LLP told U.S. District Court Judge Jan E. DuBois that alleged injuries stemming from a 2005 settlement agreement between two predecessor companies now owned by AbbVie and Teva were too speculative for...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.